Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Panagides

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Psychopharmacology Bulletin|May 22, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationaleLarry Alphs, John Panagides, Scott Lancaster
The Journal of Clinical Psychiatry|October 27, 2007
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialSteven G Potkin, Miriam Cohen, John Panagides
Academic Radiology|October 25, 2021
Synchronous Video-Based Virtual Visits in Interventional Radiology During the COVID-19 Pandemic - A Double-Edged Sword: Challenges and Opportunities for Improving CareNikhita Nambiar, John Panagides, Melissa Chittle, et al.
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief TrainingLarry Alphs, Robert Morlock, Cheryl Coon, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJohn M Kane, Michael Cohen, Jun Zhao, et al.
The Journal of Urology|June 28, 2021
Top-Down versus Bottom-Up Approach in Children Presenting with Urinary Tract Infection: Comparative Effectiveness Analysis Using RIVUR and CUTIE DataHsin-Hsiao Scott Wang, Dylan Cahill, John Panagides, et al.
International Journal of Methods in Psychiatric Research|May 4, 2011
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophreniaLarry Alphs, Robert Morlock, Cheryl Coon, et al.
The AAPS Journal|December 25, 2010
Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptomsRik de Greef, Alan Maloney, Per Olsson-Gisleskog, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
International Journal of Geriatric Psychiatry|July 15, 2011
Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosisSteven L Dubovsky, Colleen Frobose, Phillip Phiri, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Psychopharmacology Bulletin|May 22, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationaleLarry Alphs, John Panagides, Scott Lancaster
The Journal of Clinical Psychiatry|October 27, 2007
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialSteven G Potkin, Miriam Cohen, John Panagides
Academic Radiology|October 25, 2021
Synchronous Video-Based Virtual Visits in Interventional Radiology During the COVID-19 Pandemic - A Double-Edged Sword: Challenges and Opportunities for Improving CareNikhita Nambiar, John Panagides, Melissa Chittle, et al.
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief TrainingLarry Alphs, Robert Morlock, Cheryl Coon, et al.
Journal of Clinical Psychopharmacology|June 4, 2010
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJohn M Kane, Michael Cohen, Jun Zhao, et al.
The Journal of Urology|June 28, 2021
Top-Down versus Bottom-Up Approach in Children Presenting with Urinary Tract Infection: Comparative Effectiveness Analysis Using RIVUR and CUTIE DataHsin-Hsiao Scott Wang, Dylan Cahill, John Panagides, et al.
International Journal of Methods in Psychiatric Research|May 4, 2011
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophreniaLarry Alphs, Robert Morlock, Cheryl Coon, et al.
The AAPS Journal|December 25, 2010
Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptomsRik de Greef, Alan Maloney, Per Olsson-Gisleskog, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
International Journal of Geriatric Psychiatry|July 15, 2011
Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosisSteven L Dubovsky, Colleen Frobose, Phillip Phiri, et al.
Pageof 3